ResMed (RMD) received a Form 144 notice for a proposed insider sale. The filing lists 8,011 common shares to be sold through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $2,000,773.19 and an approximate sale date of November 7, 2025.
The shares were acquired via an option originally granted on November 14, 2018, with acquisition and cash payment dated November 7, 2025. As context, the filing shows 145,966,294 shares outstanding. Recent activity disclosed in the notice includes three prior sales of 8,009 shares each on August 7, 2025, September 8, 2025, and October 7, 2025, with gross proceeds of $2,238,378.55, $2,227,590.42, and $2,265,332.03, respectively.
The notice indicates sales may occur using standard brokerage methods on a national exchange.
ResMed (RMD) reported a Form 4 for CFO Brett Sandercock. On 11/03/2025, he exercised 2,000 stock options at $101.64 (code M) and sold 3,000 shares at $247.54 (code S). Following these transactions, he directly beneficially owns 85,745 shares. The activity was conducted under a Rule 10b5-1 plan adopted on February 19, 2025. The exercised options were from a grant first exercisable on 11/11/2019 and vest 1/3 per year, expiring 11/14/2025.
Form 144 filing: An affiliate, Brett Sandercock, filed notice to sell 3,000 shares of the issuer’s Common stock through Fidelity Brokerage Services on the NYSE, reflecting an aggregate market value of $742,620 and an approximate sale date of 11/03/2025.
The shares derive from two sources: 2,000 shares tied to an option granted on 11/14/2018 (cash payment dated 11/03/2025) and 1,000 shares from restricted stock vesting on 11/11/2022 (compensation). Shares outstanding were 145,966,294.
Recent activity shows prior sales by the same filer of 3,000 shares on 09/02/2025 for $812,310 and 3,000 shares on 10/01/2025 for $823,080. This notice outlines a proposed disposition method and quantity; actual sales depend on market conditions and execution.
ResMed Inc. (RMD) reported stronger Q1 FY26 results. Net revenue was $1,335,582 thousand, up 9% year over year. Gross margin improved to 61.5% from 58.6%, reflecting manufacturing and component cost efficiencies. Net income was $348,536 thousand, with diluted EPS of $2.37 versus $2.11 a year ago.
Sleep and Breathing Health revenue reached $1,169,446 thousand (up 10%), driven by higher device and mask unit sales across the U.S., Canada and Latin America and in combined Europe, Asia and other markets. Residential Care Software delivered $166,136 thousand (up 6%), led by MEDIFOX DAN, partly offset by softer Senior Living and Long‑Term Care.
Operating cash flow was $457,321 thousand. Cash and cash equivalents were $1,383,848 thousand. The company repurchased $150,010 thousand of shares and declared a $0.60 per share dividend. Total debt was $668,560 thousand, with long-term debt down and short-term borrowings up. Restructuring expenses of $15,810 thousand were recorded for workforce planning. The Federal Circuit affirmed PTAB decisions invalidating NYU’s asserted patent claims, while certain Cleveland Medical PTAB reviews proceed with decisions expected by July 2026.
The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD). As of 09/30/2025, Vanguard reported 20,007,417.40 shares beneficially owned, representing 13.66% of the class. The filing notes the holdings are in the form of depository receipts.
Vanguard reported 0 shares with sole voting power and 1,834,309.40 with shared voting power. It reported 17,643,708.00 shares with sole dispositive power and 2,363,709.40 with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. Its clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.